Baltimore News Journal – Lifestyle
Author:
Recludix Pharma, Inc.
Recludix Pharma Announces Upcoming Oral Presentations on Preclinical Data for Oral STAT6 Inhibitor REX-8756 and Topical STAT 1/3 Inhibitors at the Society for Investigative Dermatology (SID) Annual Meeting
May 4, 2026
Recludix Pharma Promotes Executive Leaders Following Recent Corporate Accomplishments
March 16, 2026